Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report

Background: Long-term follow-up on a clinical trial of 15 stage III-IV NSCLC patients treated with an Indoleamine 2,3-Dioxygenase (IDO) peptide vaccine (NCT01219348). Methods: Fifteen HLA-A2-positive patients with stable stage III-IV NSCLC after standard chemotherapy were treated with subcutaneous v...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjeldsen, Julie Westerlin, Iversen, Trine Zeeberg, Engell-Noerregaard, Lotte, Mellemgaard, Anders, Andersen, Mads Hald, Svane, Inge Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157336/
https://www.ncbi.nlm.nih.gov/pubmed/30283461
http://dx.doi.org/10.3389/fimmu.2018.02145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157336/
https://www.ncbi.nlm.nih.gov/pubmed/30283461
http://dx.doi.org/10.3389/fimmu.2018.02145

Ejemplares similares